Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide

Brown, 1969, Preparation of highly active enterogastrone, Canadian Journal of Physiology and Pharmacology, 47, 113, 10.1139/y69-020 Brown, 1970, Further purification of a polypeptide demonstrating enterogastrone activity, Journal of Physiology, 209, 57, 10.1113/jphysiol.1970.sp009155 Brown, 1971, A gastric inhibitory polypeptide. II. The complete amino acid sequence, Canadian Journal of Biochemistry, 49, 867, 10.1139/o71-122 Brown, 1971, A Gastric inhibitory polypeptide. I. The amino acid composition and the tryptic peptides, Canadian Journal of Biochemistry, 49, 255, 10.1139/o71-037 Pederson, 1972, Inhibition of histamine-, pentagastrin-, and insulin-stimulated canine gastric secretion by pure gastric inhibitory polypeptide, Gastroenterology, 62, 393, 10.1016/S0016-5085(72)80144-6 Dupré, 1973, Stimulation of insulin secretion by gastric inhibitory polypeptide in man, The Journal of Clinical Endocrinology and Metabolism, 37, 826, 10.1210/jcem-37-5-826 Pederson, 1975, Gastric inhibitory polypeptide. Its physiologic release and insulinotropic action in the dog, Diabetes, 24, 1050, 10.2337/diabetes.24.12.1050 Pederson, 1976, The insulinotropic action of gastric inhibitory polypeptide in the perfused rat pancreas, Endocrinology, 99, 780, 10.1210/endo-99-3-780 Pederson, 1978, Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secreton from the perfused rat pancreas, Endocrinology, 103, 610, 10.1210/endo-103-2-610 Creutzfeldt, 1979, The incretin concept today, Diabetologia, 16, 75, 10.1007/BF01225454 Brown, 1976, GI hormones and insulin secretion, Endocrinology, Proceedings of the Fifth International Congress in Endocrinology, 2, 568 Bell, 1983, Exon duplication and divergence in the human preproglucagon gene, Nature, 304, 368, 10.1038/304368a0 Bell, 1983, Hamster preproglucagon gene contains the sequence of glucagon and two related peptides, Nature, 302, 716, 10.1038/302716a0 Nauck, 1993, Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7–36) amide infused at near-physiological insulinotropic hormone and glucose concentrations, The Journal of Clinical Endocrinology and Metabolism, 76, 912, 10.1210/jc.76.4.912 Jörnvall, 1981, Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP), Federal European Biochemistry Society Letters, 123, 205, 10.1016/0014-5793(81)80288-8 Amland, 1984, Similar plasma GIP responses in obese and lean subjects after an oral test meal and after intraduodenal stimulation with fat and glucose, International Journal of Obesity, 8, 649 Buffa, 1975, Identification of the intestinal cell storing gastric inhibitory polypeptide, Histochemistry, 43, 249, 10.1007/BF00499706 Buchan, 1978, Electron immunocytochemical evidence of the K cell localisation of gastric inhibitory polypeptide (GIP) in man, Histochemistry, 56, 37, 10.1007/BF00492251 Takeda, 1987, Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor, Proceedings of the National Academy of Science, USA, 84, 7005, 10.1073/pnas.84.20.7005 Inagaki, 1989, Gastric inhibitory polypeptide: structure and chromosomal location of the human gene, Molecular Endocrinology, 3, 1014, 10.1210/mend-3-6-1014 Tseng, 1993, Glucose-dependent insulinotropic peptide: structure of the precursor and tissue-specific expression in rat, Proceedings of the National Academy of Science, USA, 90, 1992, 10.1073/pnas.90.5.1992 Jepeal, 2003, Cell-specific expression of the glucose-dependent insulinotropic polypeptide gene functions through a GATA and an ISL-1 motif in a mouse neuroendocrine tumor cell line, Regulatory Peptides, 113, 139, 10.1016/S0167-0115(03)00046-6 Tseng, 1994, Regulation of glucose-dependent insulinotropic peptide gene expression by a glucose meal, American Journal of Physiology, 266, G887 Cleator, 1975, Release of immunoreactive gastric inhibitory polypeptide (IR-GIP) by oral ingestion of food substances, American Journal of Surgery, 130, 128, 10.1016/0002-9610(75)90360-8 Krarup, 1985, Responses and heterogeneity of IR-GIP after intraduodenal glucose and fat, American Journal of Physiology, 249, E195 Mortensen, 2003, are colocalized in a subset of endocrine cells in the small intestine, Regulatory Peptides, 114, 189, 10.1016/S0167-0115(03)00125-3 Ebert, 1980, Decreased GIP secretion through impairment of absorption, 192, 10.1159/000388400 Besterman, 1979, Gut hormones in tropical malabsorption, British Medical Journal, vol. II, 1252, 10.1136/bmj.2.6200.1252 Besterman, 1978, Gut-hormone profile in coeliac disease, Lancet, i, 785, 10.1016/S0140-6736(78)92994-X Ebert, 1976, Response of gastric inhibitory polypeptide (GIP) to test meal in chronic pancreatitis—relationship to endocrine ans exocrine insufficiency, Diabetologia, 12, 609, 10.1007/BF01220638 Fushiki, 1992, An extract of Gymnema sylvestre leaves and purified gymnemic acid inhibits glucose-stimulated gastric inhibitory peptide secretion in rats, Journal of Nutrition, 122, 2367, 10.1093/jn/122.12.2367 Ebert, 1980, Reversal of impaired GIP and insulin secretion in patients with pancreatogenic steatorrhea following enzyme substitution, Diabetologia, 19, 198, 10.1007/BF00275269 Crockett, 1976, Gastric inhibitory polypeptide (GIP) in maturity-onset diabetes mellitus, Diabetes, 25, 931, 10.2337/diabetes.25.10.931 Ross, 1977, Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus, Diabetes, 26, 525, 10.2337/diabetes.26.6.525 Jones, 1989, The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus, Diabetologia, 32, 668, 10.1007/BF00274255 Vilsbøll, 2001, Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients, Diabetes, 50, 609, 10.2337/diabetes.50.3.609 Toft-Nielsen, 2001, Determinants of impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients, The Journal of Clinical Endocrinology and Metabolism, 86, 3717, 10.1210/jc.86.8.3717 Mentlein, 1993, Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum, European Journal of Biochemistry, 214, 829, 10.1111/j.1432-1033.1993.tb17986.x Pauly, 1996, Investigation of glucose-dependent insulinotropic polypeptide-(1–42) and glucagon-like peptide-1-(7–36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel kinetic approach, Journal of Biology and Chemistry, 271, 23222, 10.1074/jbc.271.38.23222 Deacon, 2000, Degradation of endogenous and exogenous gastric inhibitory polypeptide (GIP) in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide, The Journal of Clinical Endocrinology and Metabolism, 85, 3575, 10.1210/jc.85.10.3575 Hansen, 1999, Glucagon-like peptide-1-(7–36)amide is transformed to glucagon-like peptide-1-(9–36)amide by dideptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine, Endocrinology, 140, 5356, 10.1210/en.140.11.5356 Deacon, 2001, Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic effects in anesthetized pigs, Diabetes, 50, 1588, 10.2337/diabetes.50.7.1588 Meier, 2004, Secretion, degradation, and elimination of glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) in patients with chronic renal insufficiency and healthy controls, Diabetes, 53, 654, 10.2337/diabetes.53.3.654 Vilsbøll, 2003, Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects, The Journal of Clinical Endocrinology and Metabolism, 88, 220, 10.1210/jc.2002-021053 Moore, 1906, On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane, Biochemistry Journal, 1, 28, 10.1042/bj0010028 Dupré, 1966, Stimulation of release of insulin by an extract of intestinal mucosa, Diabetes, 15, 555, 10.2337/diab.15.8.555 Nauck, 1993, Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus, Journal of Clinical Investigation, 91, 301, 10.1172/JCI116186 Meier, 2001, Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes, Diabetes, 50, 2497, 10.2337/diabetes.50.11.2497 Vilsbøll, 2002, Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients, Diabetologia, 45, 1111, 10.1007/s00125-002-0878-6 Vilsbøll, 2003, Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects, Regulatory Peptides, 114, 115, 10.1016/S0167-0115(03)00111-3 Meier, 2004, Gastric inhibitory polypeptide (GIP) does not inhibit gastric emptying in man, American Journal of Physiology (Endocrinology and Metabolism), 286, E621, 10.1152/ajpendo.00499.2003 Meier, 2003, Similar insulin secretory response to a GIP bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects, Metabolism, 52, 1579, 10.1016/S0026-0495(03)00327-5 Vilsbøll, 2003, The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype, The Journal of Clinical Endocrinology and Metabolism, 88, 4897, 10.1210/jc.2003-030738 Meier, 2003, Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia, Diabetologia, 46, 798, 10.1007/s00125-003-1103-y Kreymann, 1987, Glucagon-like peptide-1 [7–36]: a physiological incretin in man, Lancet, 2, 1300, 10.1016/S0140-6736(87)91194-9 Nauck, 1993, Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients, Diabetologia, 36, 741, 10.1007/BF00401145 Creutzfeldt, 1978, Gastric inhibitory polypeptide (GIP) and insulin in obesity: Increased response to stimulation and defective feedback control of serum levels, Diabetologia, 14, 15, 10.1007/BF00429703 Salera, 1982, Gastric inhibitory polypeptide release after oral glucose: relationship to glucose intolerance, diabetes mellitus and obesity, The Journal of Clinical Endocrinology and Metabolism, 55, 329, 10.1210/jcem-55-2-329 Ross, 1978, Effects of ingestion of triglyceride or galactose on secretion of gastric inhibitory polypeptide and on response to intravenous glucose in normal and diabetic subjects, Diabetes, 27, 327, 10.2337/diabetes.27.3.327 Falko, 1975, Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man, The Journal of Clinical Endocrinology and Metabolism, 41, 260, 10.1210/jcem-41-2-260 Yip, 2000, GIP biology and fat metabolism, Life Sciences, 66, 91, 10.1016/S0024-3205(99)00314-8 Usdin, 1993, Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor familiy, is widely distributed in peripheral organs and the brain, Endocrinology, 133, 2861, 10.1210/en.133.6.2861 Eckel, 1979, Gastric inhibitory polypeptide enhance lipoprotein lipase activity in cultured preadipocytes, Diabetes, 28, 1141, 10.2337/diabetes.28.12.1141 Hauner, 1988, Effects of gastric inhibitory polypeptide on glucose and lipid metabolism of isolated rat adipocytes, Annals of Nutrition and Metabolism, 32, 282, 10.1159/000177467 Wasada, 1981, Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs, Journal of Clinical Investigation, 68, 1107, 10.1172/JCI110335 Ebert, 1991, Effect of exogenous or endogenous gastric inhibitory polypeptide (GIP) on plasma triglyceride response in rats, Hormone and Metabolic Research, 23, 517, 10.1055/s-2007-1003745 Ohneda, 1983, Effect of enogenous gastric inhibitory polypeptide (GIP) on the removal of triacylglycerol in dogs, Regulatory Peptides, 6, 25, 10.1016/0167-0115(83)90131-3 Miyawaki, 2002, Inhibition of gastric inhibitory polypeptide signaling prevents obesity, Nature Medicine, 8, 738, 10.1038/nm727 Gault, 2003, Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?, Neuropeptides, 37, 253, 10.1016/j.npep.2003.09.002 Kieffer, 2003, GIP or not GIP? That is the question, Trends of Pharmacology Science, 24, 110, 10.1016/S0165-6147(03)00031-2 Tseng, 1996, Postprandial stimulation of insulin release by glucose-dependent insulinotropic peptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat, Journal of Clinical Investigation, 98, 2440, 10.1172/JCI119060 Miyawaki, 1999, Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice, Proceedings of the National Academy of Science, USA, 96, 14843, 10.1073/pnas.96.26.14843 Wolfe, 1983, Effects of antibodies to gastric inhibitory peptide on gastric acid secretion and gastrin release in the dog, Gastroenterology, 84, 941, 10.1016/0016-5085(83)90195-6 Maxwell, 1980, Effect of gastric inhibitory polypeptide on pentagastrin-stimulated acid secretion in man, Digestive Diseases and Sciences, 24, 113, 10.1007/BF01308308 Nauck, 1992, Lack of effect of synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7–36 amide] infused at near-physiological concentrations on pentagastrin-stimulated gastric acid secretion in normal human subjects, Digestion, 52, 214, 10.1159/000200956 Thor, 1987, Role of GIP and insulin in glucose-induced changes in intestinal motility patterns, American Journal of Physiology, 252, G8 Nicholl, 1989, Effect of enprostil on gastric emptying, intestinal transit time and post-prandial release of gastro-intestinal peptides, Digestion, 43, 47, 10.1159/000199860 Wettergren, 1993, Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man, Digestive Diseases and Sciences, 38, 665, 10.1007/BF01316798 Nauck, 1997, Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans, American Journal of Physiology (Endocrinology and Metabolism), 273, E981, 10.1152/ajpendo.1997.273.5.E981 Meier, 2003, Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes, The Journal of Clinical Endocrinology and Metabolism, 88, 2719, 10.1210/jc.2003-030049 Gromada, 1998, Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1, Pflügers Archives, 435, 583, 10.1007/s004240050558 Kosaka, 1930, Demonstration of the humoral agent in fat inhibition on gastric secretion, Proceedings of the Society of Experimental Biology Medicine, 27, 890, 10.3181/00379727-27-5024 Creutzfeldt, 1985, New developments in the incretin concept, Diabetologia, 28, 565, 10.1007/BF00281990 Elrick, 1964, Plasma insulin response to oral and intravenous glucose administration, The Journal of Clinical Endocrinology and Metabolism, 24, 1076, 10.1210/jcem-24-10-1076 Shuster, 1988, Incretin effect due to increased secretion and decreased clearance of insulin in normal humans, Diabetes, 37, 200, 10.2337/diabetes.37.2.200 Nauck, 1986, Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses, The Journal of Clinical Endocrinology and Metabolism, 63, 492, 10.1210/jcem-63-2-492 Krarup, 1988, Immunoreactive gastric inhibitory polypeptide, Endocrine Reviews, 9, 122, 10.1210/edrv-9-1-122 Kosaka, 1930, Demonstration of the humoral agent in fat inhibition of gastric acid secretion, Proceedings of the Society of Experimental Biology Medicine, 27, 870, 10.3181/00379727-27-5024 Gutniak, 1992, Antidiabetogenic effect of glucagon-like peptide-1 (7–36)amide in normal subjects and patients with diabetes mellitus, New England Journal of Medicine, 326, 1316, 10.1056/NEJM199205143262003 Amland, 1985, Effects of intravenously infused porcine GIP on serum insulin, plasma C-peptide, and pancreatic polypeptide in non-insulin-dependent diabetes in the fasting state, Scandinavian Journal of Gastroenterology, 20, 315, 10.3109/00365528509091657 Jorde, 1987, The insulinotropic effect of gastric inhibitory polypeptide in non-insulin dependent diabetes, Italian Journal of Gastroenterology, 19, 76 Krarup, 1988, Effect of porcine gastric inhibitory polypeptide on β-cell function in type I and type II diabetes mellitus, Metabolism, 36, 677, 10.1016/0026-0495(87)90153-3 Holst, 1997, The pathogenesis of NIDDM involves a defective expression of the GIP receptor, Diabetologia, 40, 984, 10.1007/s001250050779 Meier, 2002, Gastric inhibitory polypeptide (GIP): the neglected incretin revisited, Regulatory Peptides, 107, 1, 10.1016/S0167-0115(02)00039-3 Van Haeften, 1991, Decreased insulin secretory capacity and normal pancreatic B-cell glucose sensitivity in non-obese patients with NIDDM, European Journal of Clinical Investigation, 21, 168, 10.1111/j.1365-2362.1991.tb01806.x Fritsche, 2000, Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion, Diabetologia, 43, 852, 10.1007/s001250051461 Ratheiser, 1990, Quantitative and qualitative differences in basal and glucose- and arginine-stimulated insulin secretion in healthy subjects and different stages of NIDDM, Acta Diabetologica Latina, 27, 197, 10.1007/BF02581332 Groop, 1987, Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects, Diabetes, 36, 1320, 10.2337/diabetes.36.11.1320 Thorens, 1993, Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9–39) an antagonist of the receptor, Diabetes, 42, 1678, 10.2337/diabetes.42.11.1678 Gallwitz, 1993, Binding specificity and signal transduction of receptors for glucagon-like peptide-1(7–36)amide and gastric inhibitory polypeptide on RINm5F insulinoma cells, Journal of Molecular Endocrinology, 10, 259, 10.1677/jme.0.0100259 Göke, 1989, Signal transmission after GLP-1(7–36)amide binding in RINm5F cells, American Journal of Physiology, 257, G397 Gromada, 1997, Multisite regulation of insulin secretion by cAMP-increasing agonists: evidence that glucagon-like peptide 1 and glucagon act via distinct receptors, Pflügers Archives, 434, 515, 10.1007/s004240050431 Jones, 1987, The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion, Diabetologia, 30, 707, 10.1007/BF00296993 O'Harte, 1998, Gastric inhibitory polypeptide and effects of glycation on glucose transport and metabolism in isolated mouse abdominal muscle, The Journal of Endocrinology, 156, 237, 10.1677/joe.0.1560237 O'Harte, 2002, Improved stability, insulin-releasing activity and anti-diabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP, Diabetologia, 45, 1281, 10.1007/s00125-002-0894-6 Gault, 2002, Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant anti-hyperglycaemic activity in spontaneous obesity-diabetes, Biochemistry Journal, 367, 913, 10.1042/bj20020319 Gault, 2002, Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide, Biochemistry Biophysics Research Communications, 290, 1420, 10.1006/bbrc.2002.6364 Hinke, 2002, Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats, Diabetes, 51, 652, 10.2337/diabetes.51.3.652 Gault, 2003, DPP IV resistance and insulin releasing activity of a novel di-substituted analogue of glucose-dependent insulinotropic polypeptide, (Ser2-Asp13)GIP, Cell Biology International, 27, 41, 10.1016/S1065-6995(02)00255-X Gault, 2003, Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotrophic polypeptide, The Journal of Endocrinology, 176, 133, 10.1677/joe.0.1760133 Gault, 2003, Degradation, cyclic adenosine monophosphate production, insulin secretion, and glycemic effects of two novel N-terminal Ala2-substituted analogs of glucose-dependent insulinotropic polypeptide with preserved biological activity in vivo, Metabolism, 52, 679, 10.1016/S0026-0495(03)00027-1 O'Harte, 1999, NH2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced anti-hyperglycemic activity, Diabetes, 48, 758, 10.2337/diabetes.48.4.758 O'Harte, 1998, Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells, Biochemistry Biophysics Acta, 1425, 319, 10.1016/S0304-4165(98)00084-1 O'Harte, 2000, Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide, The Journal of Endocrinology, 165, 639, 10.1677/joe.0.1650639 O'Harte, 2001, DPP IV resistant N-terminally modified GIP analogues with enhanced insulinotropic activity, Diabetologia, 44, A194 Eissele, 1992, Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man, The European Journal of Clinical Investigation, 22, 283, 10.1111/j.1365-2362.1992.tb01464.x Ørskov, 1994, Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans, Diabetes, 43, 535, 10.2337/diabetes.43.4.535 Schjoldager, 1989, GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans, Digestive Diseases and Sciences, 34, 703, 10.1007/BF01540341 Sauerwald, 1997, Influence of glucagon-like peptide 1 on fasting hyperglycaemia in NIDDM patients treated with insulin (sulfonylurea failure), Diabetologia, 40, A46 Perfetti, 2000, Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats, Endocrinology, 141, 4600, 10.1210/en.141.12.4600 Trümper, 2001, Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling, Molecular Endocrinology, 15, 1559, 10.1210/me.15.9.1559 Nauck, 1989, Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man; interactions with glucose, phenylalanine, and cholezystokinin-8, The Journal of Clinical Endocrinology and Metabolism, 69, 654, 10.1210/jcem-69-3-654 Fieseler, 1995, Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-I but not by CCK-8, American Journal of Physiology, 268, E949